Robert Broussard, MD
Pulmonary Disease · Lake Charles, LANPI 1821007170
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.6% of the total across 759 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 36 manufacturers reported payments, led by GSK at 24.7% of the total.
Across 759 payments — averaging $19.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$4K
- AstraZeneca$3K
- Sanofi$1K
- Boehringer Ingelheim$793
- CSL Behring$786
- Regeneron Healthcare Solutions, Inc.$780
- plus $5K from 30 others
What the payments were for
- Food & beverage$14,84899%
- Education$2071%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 230 | $3,725 |
| AstraZeneca | 115 | $2,532 |
| Sanofi | 55 | $1,088 |
| Boehringer Ingelheim | 39 | $793 |
| CSL Behring | 36 | $786 |
| Regeneron Healthcare Solutions, Inc. | 35 | $780 |
| Grifols USA, LLC | 30 | $665 |
| Mylan Specialty L.p. | 30 | $543 |
| Amgen | 22 | $457 |
| Baxter Healthcare | 17 | $454 |
| Actelion Pharmaceuticals US, Inc. | 23 | $407 |
| Insmed, Inc. | 18 | $403 |
| Merck | 19 | $379 |
| Viatris Specialty LLC | 9 | $291 |
| Verona Pharma, Inc. | 9 | $201 |
| United Therapeutics Corporation | 11 | $196 |
| ANI Pharmaceuticals, Inc. | 7 | $191 |
| Philips North America LLC | 12 | $182 |
| Bayer | 9 | $182 |
| Sanofi-aventis U.S. LLC | 3 | $123 |
| Abiomed | 1 | $122 |
| Novartis | 6 | $111 |
| Genentech USA, Inc. | 5 | $90 |
| Johnson & Johnson | 3 | $54 |
| Pfizer | 2 | $40 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $37 |
| Gilead | 2 | $37 |
| Mallinckrodt Enterprises LLC | 1 | $33 |
| Vifor Pharma, Inc. | 1 | $26 |
| Intuitive Surgical | 1 | $25 |
| Circassia Inc. | 1 | $23 |
| Mallinckrodt Hospital Products Inc. | 1 | $18 |
| Electromed, Inc. | 1 | $17 |
| Inogen, Inc. | 1 | $17 |
| Advanced Respiratory, Inc | 1 | $16 |
| Tetraphase Pharmaceuticals, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$15,055 in reported general payments places this provider in the 85th percentile of 189 pulmonary disease providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 546 | $440,037 |
| OfevNintedanib Esylate | 12 | $159,897 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 13 | $140,933 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 123 | $98,083 |
| Dupixent PenDupilumab | 25 | $95,384 |
| Ambrisentan | 12 | $91,959 |
| TezspireTezepelumab-Ekko | 22 | $87,303 |
| Fasenra PenBenralizumab | 13 | $74,002 |
| Breo ElliptaFluticasone/Vilanterol | 161 | $68,040 |
| EliquisApixaban | 52 | $42,273 |
| Spiriva RespimatTiotropium Bromide | 64 | $36,743 |
| SymbicortBudesonide/Formoterol Fumarate | 92 | $28,903 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 38 | $17,961 |
| XareltoRivaroxaban | 24 | $13,417 |
| Theophylline ErTheophylline Anhydrous | 107 | $9,229 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $3,725 | $526,038745 claims |
| AstraZenecaBreztri Aerosphere, Tezspire, Symbicort, Bevespi Aerosphere | $2,532 | $220,630252 claims |
| Boehringer IngelheimOfev, Spiriva Respimat | $793 | $196,63976 claims |
| Grifols USA, LLCProlastin C | $665 | $140,93313 claims |
| PfizerEliquis | $40 | $42,27352 claims |
| Johnson & JohnsonXarelto | $54 | $13,41724 claims |
| MerckDulera | $379 | $8,45717 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 189 pulmonary disease providers in Louisiana.
Other pulmonary disease in Lake Charles
- Gary KohlerLake Charles$21K
- Luke WilliamsLake Charles$16K
- Clifford CourvilleLake Charles$15K
- Tashfeen MahmoodLake Charles$14K
- Andrea EspinozaHouma$655K
- Joseph LaskyNew Orleans$447K
- Hollis O NealBaton Rouge$418K
- Ramsy AbdelghaniNew Orleans$308K
- Juzar AliNew Orleans$216K
- Warren BotnickNatchitoches$213K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.